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Background: Milk-derived bioactive peptides retain many biological properties and have therapeutic effects in
cardiovascular disorders such as atherosclerosis. Under inflammatory conditions the expression of endothelial cells
adhesion molecules is induced, increasing monocyte adhesion to human vessel wall, a critical step in the
pathogenesis of atherosclerosis. In the present work we explored the effects of milk-derived bioactive peptides on
the expression of the inflammatory phenotype of human endothelial cells and their effects on monocyte adherence
to endothelial cells.
Results: Treatment of endothelial cells with milk-derived hydrolysate inhibited their production of inflammatory
proteins MCP-1 and IL-8 and expression of VCAM-1, ICAM-1 and E-selectin. Milk derived hydrolysate also attenuated
the adhesion of human monocytes to activated endothelial cells. The effect was similar to that obtained in
endothelial cells treated with troglitazone, a ligand of peroxisome proliferators-activator receptor-gamma (PPAR-γ).
PPAR-γ is a transcription factor which when activated antagonises the pro-inflammatory capability of nuclear factor
κB (NF-κB). We further examined whether the effects of milk-derived hydrolysates on endothelial cells may be
mediated through NF-κB activation via a PPAR-γ dependent mechanism. The specific PPAR-γ inhibitor, GW9662
blocked the effects of the hydrolysate on the NF-κB-mediated chemokines and adhesion molecules expression in
endothelial cells.
Conclusions: These results suggest that milk-derived bioactive peptides work as anti-atherogenic agents through
the inhibition of endothelial-dependent adhesive interactions with monocytes by inhibiting the NF-κB pathway
through a PPAR-γ dependent mechanism.
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Atherosclerosis is a chronic inflammatory disease of ar-
teries characterized by the formation of an atheroscler-
otic plaque, which is formed by abnormal deposition of
lipids, infiltration of inflammatory cells and cellular pro-
liferation [1-3]. There is growing evidence that con-
sumption of low-fat milk and dairy product may be
beneficial in the prevention or treatment of cardiovascu-
lar disease [4]. Elwood PC et al., in a meta-analysis study
showed that the consumption of dairy products is a* Correspondence: simone.marcone@ucd.ie
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unless otherwise stated.protective factor for preventing ischemic vascular dis-
ease, stroke and diabetes [5]. Bovine milk contains a
range of bioactive molecules such as lysozyme, lactofer-
rin, immunoglobulins, growth factors and hormones [6].
The beneficial effects of milk components and dairy
products may be due to the biological properties of na-
tive proteins or to bioactive peptides derived from these
proteins, making them potential ingredients of health-
promoting foods [7].
Milk-derived bioactive peptides can be encrypted in
both casein (α-, β- and γ-casein) and whey proteins
(β-lactoglobulin, α-lactalbumin, serum albumin, immu-
noglobulins, lactoferrin, protease-peptone fractions). Casein
hydrolysate containing peptides from casein is obtained in
several ways, such as enzymatic hydrolysis or microbialal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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microorganisms or plants [8,9]. These bioactive peptides
may exert a range of physiological effects on the cardiovas-
cular, digestive, endocrine, immune and nervous systems
[10-12]. Several published studies have demonstrated the
effects of milk constituents in vitro [13,14], while studies in
animal and human models suggest that bioactive peptides
derived from milk may have beneficial effects in cardiovas-
cular disorders, reduce arterial stiffness and improve endo-
thelial activity [15-17]. Endothelial dysfunction plays a
central role in the initiation and pathogenesis of athero-
sclerosis [18,19]. Monocytes adhering to activated vascular
endothelial cells (EC) and migrating into the extravascular
space characterise the early inflammatory phase of athero-
genesis [20]. Many stimuli (i.e. oxidised low-density lipo-
protein cholesterol, diabetes mellitus, hypertension) injure
and modify the vascular endothelium, increasing expres-
sion of adhesion molecules, such as VCAM-1, ICAM-1
and E-selectin, thus promoting vascular permeability and
facilitating monocyte recruitment [21].
There are a number of endogenous pathways, includ-
ing activation of the peroxisome proliferators-activator
receptor-gamma (PPAR-γ), which regulate initiation and
pathogenesis of atherosclerosis. Natural and synthetic
agonists of PPAR-γ prevent endothelial cell activation and
inflammatory cell adhesion in response to injury [22].
PPAR-γ acts as a transcription factor to suppress the
signal transduction and consequent activation of pro-
inflammatory transcription factors such as nuclear factor
κB (NF-κB) [23]. PPAR-γ is just one of a nuclear hormone
receptor superfamily, whose activities are regulated
through the high affinity binding of a broad range of nat-
ural and synthetic ligands, including polyunsaturated fatty
acids and prostaglandin derivatives [24,25]. PPAR-γ is
expressed at high levels in adipose tissues and has been
found in many other cells, including those in the vas-
culature such as endothelial cells [26]. PPAR-γ agonists
may have anti-inflammatory and anti-atherogenic effects
through the ability to inhibit several steps in the develop-
ment of inflammation, in particular leukocyte infiltration
into tissues mediated by NF-kB dependent expression of
adhesion molecules [27-30].
This study explores the effects of casein-derived bio-
active peptides on the expression of the inflammatory
phenotype of EC and their effects on monocyte adherence
to EC induced by TNF-α. We demonstrate that casein hy-
drolysate inhibits the pro-inflammatory NF-κB pathway
through activation of PPAR-γ, reducing the expression of
adhesion molecules and chemokine production in EC.
Methods
Materials
Recombinant human TNF-α was purchased from R & D
Systems (McKinley Place, MN). GW9662, troglitazoneand MTT (3-(4, 5-dimethylthiazolyl-2)-2,5-diphenyltet-
razolium bromide) were purchased from Sigma-Aldrich
(Dorset, UK). Anti-phospho-p65 (serine-536) antibody
was purchased from Cell Signaling (Beverly, MA). All
other reagents used in this study were of the highest
purity and, unless otherwise stated, were obtained from
Sigma-Aldrich (Dorset, UK).
Preparation of the hydrolysate
Enterococcus strain DPC763 was originally isolated from
an Irish dairy processing plant and deposited in the
Moorepark Dairy Products Culture Collection (Teagasc,
Cork, Ireland). The strain was routinely cultured in GM17
medium prepared from M17 (Oxoid, Basingstoke, UK) sup-
plemented with 1% (w/v) glucose (Sigma-Aldrich, Dorset,
UK). Prior to inoculation into 2.5% (w/v) sodium caseinate
obtained from bovine milk (Kerry Food Ingredients) sup-
plemented with 0.5% (w/v) glucose (Sigma-Aldrich, Dorset,
UK), a single colony was cultured in 10 ml of GM17 and
incubated aerobically for 24 h at 30°C under shaking condi-
tions (100 rpm). A 1% (v/v) cell suspension was removed
and added to fresh GM17 and incubated as above. Cells
were then harvested by centrifugation (5000 rpm™ 15 min)
and washed in an equal volume of sterile water, re-spun
and suspended in water at a tenth of the original volume.
The concentrated cell paste was added at 1% (v/v) to the
sodium caseinate medium in a pH controlled bioreactor
(set-point pH 6.5) set at 30°C with 100-rpm agitation for
40 h. 1 M NaOH was used for base addition. At the end of
the incubation the material was heated to 80°C for 90 min
in a water bath, cooled overnight at 4°C, transferred to a
round-bottom flask, frozen during rotation in a methanol
bath and stored at −20°C. Powders were produced using a
Labconco freeze-dryer (Kansas City, USA) and the sample
tested in the current study represents the product of four
incubation reactions; powders were stored at 4°C. For ex-
periments, the freeze-dried powders were reconstituted in
ultra-pure water (20 mg/ml), centrifuged at 5000 rpm for
5 min and filter sterilized using 0.22 μm membrane.
Samples prepared as described above but without added
Enterococcus strain DPC763 were used as the control. Re-
generated sample of the hydrolysate was obtained by incu-
bating a different batch of sodium caseinate with a different
batch of Enterococcus strain DPC763; the incubation of EC
with the regenerated sample showed similar results to the
data obtained with the original hydrolysate prepared previ-
ously, confirming the reproducibility of the procedure and
of the study (Additional file 1: Figure S1).
Gel permeation HPLC
Gel permeation HPLC of the Enterococcus incubated so-
dium caseinate medium were performed using a TSK
G2000 SW column (600 × 7.5 mm, from Tosu Hass,
Japan) fitted to a Waters (Millipore, Midlesex, UK)
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1 ml/min using 30% (v/v) acetonitrile containing 0.1%
TFA as mobile phase and the eluant was continuously
monitored at A214 using a Waters Model 441 fixed
wavelength detector. Powder based samples were dis-
solved in sterile water at 25 mg/ml and left at 4°C over-
night. All samples were filtered through a 0.22 μm filter
prior to injection. Chromatographic data were collected
and analyzed using a Minichrom™ data handling system
(VG, Data Systems, Cheshire, UK). A molecular weight
calibration curve was prepared from average retention
volumes of standard proteins and peptides.
Cell culture
Human aortic endothelial cells (EC) were obtained from
Cascade biologics – Invitrogen cell culture (Carlsbad, CA)
and were grown in “endothelial cell culture media MV”
plus growth supplements from Promo Cell (Heidelberg,
DE) and supplemented with 100 units/ml penicillin and
100 ug/ml streptomycin. For experiments, 80% confluent
EC were incubated in endothelial cell basal media from
Promo Cell (2% foetal calf serum, 0.4% endothelial cell
growth supplements, 90 μg/ml heparin and with 100units/
ml penicillin and 100 ug/ml streptomycin) for 24 h before
treatments. Human THP-1 monocytes were purchased
from the LGC Promochem (Middlesex, UK) and cultured
in RPMI medium supplemented with 10% foetal bovine
serum, L-glutamine (2 mM) and antibiotics (100 U/mL
penicillin, 100 μg/mL streptomycin). Cells were grown in
a humidified atmosphere of 5% CO2/95% air at 37°C.
DMSO 3 μl in 2 ml of media was used as the vehicle con-
trol for each sample.
Cell viability assay
EC were seeded in a 96-well tissue culture plate (2 × 104
cells per well) for 24 h before the experiment. EC were
then treated with various concentrations of sodium ca-
seinate hydrolysates (3, 30, 300 and 600 μg/ml) for 18 h.
After treatment, the medium was removed and 40 μl of
fresh medium plus 10 μl of MTT solution (5 mg/ml in
PBS, 0.22 μm filter sterilized) were added to the wells
and incubated for 3 h at 37°C. Subsequently, 100 μl of
DMSO was added into each well to dissolve the purple
precipitate formed. The absorbance was recorded at
570 nm in a microtitre plate reader (Spectramax M2,
Molecular devices, CA). The average values were deter-
mined from triplicate readings and the average value for
the blank was subtracted from the samples. Cell viability
assay was repeated in triplicate and the average value
was expressed as a percentage of vehicle control.
RNA isolation and Real-Time PCR analysis
Following treatments with sodium casein hydrolysate
(18 h) and stimulation with TNF-α (0.5 ng/ml for 6 h)the EC were washed twice with PBS, before adding
300 μl of RLT buffer (Qiagen, UK). Total RNA was iso-
lated from EC lysates using the RNeasy kit (Qiagen,
UK). Reverse transcription was carried out on 1000 ng
of total RNA using reverse transcriptase (Promega) ac-
cording to the manufacturers’ instructions. Quantification
of gene expression by real-time PCR was performed on an
ABI Prism 7700 Sequence Detection System, (Applied
Biosystems Inc., UK). VCAM-1, ICAM-1, E-sel, MCP-1
and IL-8 gene expression was examined using specific
Taqman gene expression assays (Applied Biosystems Inc.,
UK). 18S was used as endogenous control in the assay.
The mRNA levels were expressed as median values of
three independent experiments. Casein hydrolysate incu-
bation time (18 h) has been selected on the basis of a
time-course experiment which showed that the maximal
effect of inhibition of adhesion molecules expression was
reached after 18 h of hydrolysate incubation (data not
shown).
Flow cytometric analysis of surface marker expression
Following treatments with casein-derived hydrolysate
(18 h) and activation with TNF-α (0.5 ng/ml for 6 h), the
EC were harvested to be stained for flow cytometric ana-
lysis. To block non-specific binding, EC were incubated in
2% BSA in PBS for 15 min before adding the antibodies.
FITC-VCAM-1, PE-ICAM-1 (BD, Rankling Lakes, NJ)
and APC-E-sel (Bio Legend, San Diega, CA) antibodies
were used to label EC in 2% BSA in PBS. The antibodies
were incubated for 30 min at RT. Following washes, the
cells were fixed in 2% paraformaldehyde. Forward and side
scatter gates were established to exclude nonviable cells
and cell debris from the analysis. The mean fluorescence
intensity of 2 × 104 cells was analysed in each sample.
Auto-fluorescence signals generated by unlabelled cells
were used as negative controls in each experiment. Flow
cytometric analysis was performed on an Accuri C6 in-
strument and analyzed with CFlow® Software (Accuri,
Ann Arbor, MI). The protein expression levels were
expressed as median fluorescence intensity of three inde-
pendent experiments.
Adhesion assay
For static adhesion assay, 4 × 104 EC were seeded in a 96
well plate for 24 h and then treated with hydrolysates for
18 h. Subsequently, EC were stimulated with TNF-α
(0.5 ng/ml) for 6 h. After treatments, the wells were washed
three times with medium and 1 × 105 fluorescein-labelled
THP-1 monocytes were added to each well and incubated
for 30 min at 37°C. After incubation, the wells were washed
three times with medium and adherent monocytes were
measured in a Spectramax M2 (Molecular devices, CA)
plate fluorescence reader with 485 nm excitation and
530 nm emission wavelength. For photomicrographs,
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plate were analyzed using a Zeiss AxioImager M1 fluores-
cent microscope. Adhesion assay experiments were re-
peated in triplicate and the average value was expressed as
a percentage of control (vehicle).
Enzyme-linked immunosorbent assay
After treatment of EC with hydrolysates (18 h), the cells
were washed and fresh medium was added to the wells;
subsequently the cells were treated with 0.5 ng/ml TNF-
α for 6 h and the supernatants subsequently collected
and cleared by centrifugation (10,000 × g for 10 min at
4°C). The concentration of MCP-1 and IL-8 in condi-
tioned media was determined by EIA using commer-
cially available kits (MSD, Gaithersburg, MD) according
to the manufacturer’s guidelines.
Western blot analysis
Proteins extracted with lysis buffer (1% Nonidet P-40,
0.1% SDS, 150 mM NaCl, 50 mM Tris–HCl, pH 7.2) from
treated EC were separated by sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) and blotted
onto 0.45 uM nitrocellulose transfer membrane (Pall Life
Sciences, New York, NY, USA). Membranes were blocked
using 5% non-fat dried milk in TBS with 0.05% Tween
(TBS-T) for 1 h and incubated overnight at 4°C with
phospho-p65 and with βactin antibodies (Cell Signaling,
Beverly, MA). Membranes were then washed with TBS-T
and incubated for 1.5 h at room temperature with either
peroxidase conjugated anti-mouse or anti-rabbit IgG (Cell
Signaling, Beverly, MA). After further washing the proteins
were visualized with super signal chemiluminescent reagent
(Pierce, Northumberland, UK). Membranes were exposed
to film and processed using an Agfa X-ray processor.
Where required, membranes were stripped by incubating
them in stripping buffer (Pierce, Northumberland, UK) for
30 min at RT, before probing with a subsequent antibody.
Optical Density (OD) quantification of different specific
bands was calculated using laser densitometry (Bio-Rad,
Hertfordshire, UK) and normalized to the OD of β-actin.
Statistical analysis
Results are expressed as mean ± SEM. Experimental
points were performed in triplicate with a minimum of
three independent experiments (n = 3). Statistical ana-
lysis of the dose–response experiments and statistical
comparisons of 3 or more samples were carried out
using one-way ANOVA. When a significant overall effect
was detected, a Dunnett post hoc correction was used
for multiple comparisons. Statistical comparison of one
condition versus control was made by using Student’s
unpaired t-test assuming unequal variance. A statistical
value of *P < 0.05 or greater was considered significant.
There was no significant difference between cells alone(untreated) and DMSO (vehicle control) treated cells;
therefore, DMSO was used as the reference treatment.
Results
Peptide size distribution of the sodium casein-derived
peptides and effects on endothelial cell viability
A gel Permeation HPLC analysis of the Enterococcus incu-
bated sodium caseinate medium was performed to assess
the peptide size distribution of the hydrolysate, obtained
from four incubation reactions pooled to generate the
respective hydrolysate powder. Most of the peptides
(86.2%) resulted with a mass <5 kDa, while only 2.2% with
a mass >20 kDa (Figure 1A). A gel Permeation chromatog-
raphy profile of the control sample showed that the mass
of its components was >20 kDa, confirming the generation
of sodium caseinate-derived peptides in the Enterococcus
incubated sodium caseinate fermentate.
We then studied the effects of the samples on the EC
viability. The incubation of EC with sodium casein hy-
drolysate for 18 h resulted in more than 94% ±3.4% vi-
able cells at concentrations of 300 mg/ml (Figure 1B),
which indicates that concentrations from 3 to 300 μg/ml
do not significantly decrease cell viability, while at a con-
centration of 600 μg/ml the number of viable cells fell to
60% ±5.8%. A similar response was obtained incubating
EC with the control sample, resulting in a cell viability
of 91% ±4.5% up to 300 μg/ml. Thus, for these experi-
ments we performed dose response assays using hydrol-
ysate concentration up to 300 μg/ml.
TNF-α-induced adhesion molecules expression is reduced
by the sodium casein-derived peptides in EC
To examine the effect of the hydrolysate on adhesion
molecule expression in EC stimulated by TNF-α, EC
were pre-treated with the hydrolysate or with the control
sample for 18 h before adding TNF-α (0.5 ng/ml) for
6 h. As shown in Figure 2A, TNF-α enhanced VCAM-1,
ICAM-1 and E-sel mRNA while the pre-treatment with
the hydrolysate significantly reduced the expression of
VCAM-1 (by 23% ±3%, 51% ±7% and 75% ±2%), ICAM-
1 (by 0% ±4%, 18% ±3% and 43% ±5%) and E-sel (by
30% ±2%, 62% ±1% and 87% ±4%) in a dose dependent
manner (with 30, 150 and 300 μg/ml of hydrolysate, re-
spectively). The control sample had no effect on the
gene expression of the adhesion molecules (dose–re-
sponse experiments using the control sample are re-
ported in Additional file 2: Figure S2). To confirm the
gene expression results, we analysed the cell surface ex-
pression of adhesion molecules in EC pre-treated with
the hydrolysate or with the control sample for 18 h and
subsequently with TNF-α (0.5 ng/ml) for 6 h. As shown
in Figure 2B, flow cytometric analysis showed a signifi-
cant dose dependent (30, 150, nand 300 μg/ml) decrease
of EC surface protein levels of VCAM-1 (by 15% ±8%,
Figure 1 Peptide size distribution of the sodium casein-derived peptides and effects on endothelial cell viability. (A) Gel permeation
chromatography of the sodium casein-derived peptides was performed to assess the peptide size distribution of the hydrolysate. Data show the
mean ± SEM of four incubation reactions. (B) MTT assay was carried out to determine the cell viability of EC treated with casein hydrolysate or
with the control sample for 18 h, resulting in more than 94% ±3.4% viable cells up to a concentration of 300 μg/ml. Data are expressed as
mean ± SEM of 3 independent experiments. Data were reported as percentage of control (untreated cells).
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and 61% ±13%) and E-sel (by 22% ±7%, 31% ±8% and
77% ±6%). The control sample had no significant effect
on the protein expression of the adhesion molecules.
Taken together, these results suggest that the ability of
the sample to modulate the gene and the cell surface ex-
pression of adhesion molecules is due to the bioactive
peptides contained in the hydrolysate generated by the
bacterial hydrolysis of sodium caseinate (Figure 2A).
The fermentation process used to produce the hydrol-
ysate is a pH controlled reaction and sodium hydroxide
is added to compensate for the organic acid produced by
the Enterococcus strain. This will lead to the formation
of sodium lactate in the final powder (~25 mg/g) that is
not in the control sample. Thus, we used two different
samples obtained from the fermentation of sodium ca-
seinate with other Enterococcus strains, to compare to
the hydrolysate studied. As shown in Additional file 2:
Figure S2, these samples do not have any significant ef-
fect on adhesion molecules expression in EC, demon-
strating that the effects of the hydrolysate studied here is
due to the specific bioactive peptides generated by the
bacterial fermentation with Enterococcus strain DPC763
and the effects are not due to a generally hydrolysed ma-
terial or pH effect.
Adhesion of human monocytes to TNF-α activated EC is
prevented by sodium casein-derived peptides
We examined the effects of the hydrolysate on the adhe-
sion of the human monocyte cell line (THP-1 cells) to
EC monolayers following treatment with the hydrolysateand TNF-α activation. As shown in Figure 3, TNF-α
stimulation significantly increased the adhesion of THP-
1 cells to EC (81% ±2%). Pre-treatment of the EC with
hydrolysate inhibited the adhesion of THP-1 cells to
TNF-α activated EC (by 22% ±10%, 49% ±11% and 55%
±6% with 30, 150 and 300 μg/ml of hydrolysate, respect-
ively) in dose response manner. On the contrary, the ad-
hesion of THP-1 cells was unchanged by the control
sample, suggesting a critical role of the bioactive pep-
tides generated in the hydrolasate in reducing monocyte
cell-line adhesion.
Sodium casein-derived peptides attenuate the TNF-α-
induced pro-inflammatory profile in EC
Given the critical role of MCP-1 and IL-8 as chemotactic
inflammatory factors in the recruitment of monocytes fol-
lowing endothelial cells injury [31], we examined whether
the hydrolysate could modulate the production of these
chemokines in EC. In these experiments (Figure 4A), the
hydrolysate significantly suppressed MCP-1 (by 25%
±10%, 37% ±15% and 63% ±6% with 30, 150 and 300 μg/
ml of hydrolysate, respectively) and IL-8 (by 8% ±4%, 31%
±2% and 62% ±7% with 30, 150 and 300 μg/ml of hydrol-
ysate, respectively) gene expression induced in EC treated
with TNF-α. As shown in Figure 4B, the hydrolysate also
decreased EC production of MCP-1 (by 28% ±6%, 59%
±4% and 59% ±4% with 30, 150 and 300 μg/ml of hydrol-
ysate, respectively) and IL-8 (by 0% ±9%, 32% ±12% and
53% ±5% with 30, 150 and 300 μg/ml of hydrolysate, re-
spectively) measured by ELISA. This reduction in MCP-1
and IL-8 production, together with the reduction in
Figure 2 TNF-α-induced adhesion molecules expression is reduced by sodium casein-derived peptides in EC. (A) VCAM-1, ICAM-1 and
E-selectin gene expression was performed on EC treated with casein hydrolysate or control sample for 18 h, followed by 6 h stimulation with
TNF-α (0.5 ng/ml). Cells were harvested in RLT buffer, RNA was extracted and reverse transcription was performed for RT-PCR analysis. (B) For the
quantification of protein surface expression of adhesion molecules, flow cytometric analysis was performed on TNF-α activated EC (6 h, 0.5 ng/ml)
pre-incubated with casein hydrosylate. Data are expressed as mean ± SEM of 3 independent experiments. Statistical analysis was carried out using
one-way ANOVA employing Dunnett correction for multiple comparisons. A statistical value of *P < 0.05 or greater was considered significant; $$$
$ (p < 0.0001) vehicle vs. control; ****P < 0.0001, ***P < 0.001 and **P < 0.01 treatments vs. control (TNF-α activated EC).
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monocyte adhesion to TNF-α activated EC.
Sodium casein-derived peptides modulate the expression
of pro-inflammatory phenotype of EC via PPAR-γ
dependent mechanisms
PPAR-γ is a nuclear receptor that suppresses inflam-
matory gene expression when activated and the inflam-
matory response in EC [32,33]. Thus, the PPAR-γ
ligand, troglitazone, limits induction of adhesion mole-
cules in EC as well as inflammatory cell adhesion to
endothelial cells in vitro [22]. Consequently, we exam-
ined the role of PPAR-γ in the anti-inflammatory
effects of the casein hydrolysate. Specifically, we
examined whether the effects of casein hydrosylate in
suppressing the inflammatory phenotype of activated
EC were blocked by the specific PPAR-γ inhibitor,
GW9662. EC were treated for 18 h with thehydrolysate or with the PPAR-γ agonist troglitazone
(25 μM) in the presence or absence of GW9662
(10 μM) and then activated with TNF-α (0.5 ng/ml for
6 h). As shown in Figure 5, troglitazone significantly
reduced the gene expression of VCAM-1 (by 68% ±
8%), ICAM-1 (by 50% ±8%) and E-sel (by 62% ±7%)
and the protein level of VCAM-1 (by 72% ±9%),
ICAM-1 (by 60% ±8%) and E-sel (by 73% ±8%). Simi-
larly, the casein hydrolysate reduced the gene expres-
sion of VCAM-1 (by 75% ±2%), ICAM-1 (by 43% ±5%)
and E-sel (by 87% ±4%) and the protein level of
VCAM-1 (by 82% ±8%), ICAM-1 (by 61% ±13%) and
E-sel (by 77% ±6%) assessed by flow cytometry analysis.
In the presence of GW9662, the effects of both trogli-
tazone and the casein hydrolysate were prevented.
These data suggest that the modulation of TNF-α-
induced adhesion molecules response by casein derived
bioactive peptides is mediated by activation of PPAR-γ.
Figure 3 Adhesion of human monocytes to TNF-α activated EC is prevented by sodium casein-derived peptides. EC were treated with
samples for 18 h, followed by 6 h stimulation with TNF-α 0.5 ng/ml) and a static adhesion assay with fluorescence-labelled THP-1 human
monocytes was performed. (A) Adherent monocytes were measured in a plate fluorescence reader with 485 nm excitation and 530 nm emission
wavelength. Data were calculated as mean +/− SEM of 3 independent experiments. Statistical analysis was carried out using one-way ANOVA
employing Dunnett correction for multiple comparisons. A statistical value of *P < 0.05 or greater was considered significant; $$$$ (p < 0.0001)
vehicle vs control; **P < 0.01 treatments vs control (TNF-α activated EC). (B) Representative fluorescence microscopy photomicrographs of
monocytes adhesion to EC are shown: vehicle (top left); TNF-α (top centre); hydrolysate 30 μg/m l+ TNF-α (top right); hydrolysate 150 μg/ml + TNF-α
(bottom left); hydrolysate 300 μg/ml + TNF-α (bottom centre); control 300 μg/ml + TNF-α (bottom right).
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suppressing NF-κB pathway activation through PPAR-γ
dependent mechanisms
The expression of adhesion receptors is known to depend
on the activation of NF-κB, following TNF-α stimulation
[34]. To explore the hypothesis that the hydrolysate exerts
its effects in EC via NF-κB through activation of PPAR-γ,
EC were treated for 18 h with the hydrolysate or troglita-
zone (25 μM) in the presence or absence of GW9662
(10 μM) and then activated with TNF-α (0.5 ng/ml for
10 min), and EC lysates analysed by Western blotting.Phosphorylation of the p65 subunit of NF-κB was used as
an index of NF-kB activation. As shown in Figure 6, TNF-α
activates the NF-κB pathway inducing the phosphorylation
of NF-κB p65 (p < 0.001, Figure 6A,B). Phosphorylation of
NF-κB p65 was significantly reduced by hydrolysate
300 μg/ml (p < 0.01, Figure 6B) in a dose dependent
manner and by the PPAR-γ ligand troglitazone (p < 0.01,
Figure 6B). In the presence of GW9662, the effects of both
the casein hydrolysate and troglitazone on NF-κB p65
phosphorylation (p < 0.01, Figure 6B) were completely sup-
pressed, demonstrating that the modulation of NF-κB
Figure 4 Sodium casein-derived peptides attenuate the TNF-α-induced production of pro-inflammatory chemokines in EC. (A) Gene
expression levels of MCP-1 and IL-8 were measured in EC treated with casein hydrolysate or control sample for 18 h, followed by 6 h stimulation
with TNF-α (0.5 ng/ml). Cells were harvested in RLT buffer, RNA was extracted and reverse transcription was performed for RT-PCR analysis. (B)
The media from EC treated with the casein hydrolysate and activated with TNF-α was assayed to measure MCP-1 and IL-8 concentration by ELISA.
Each experiment was carried out independently three times. Data were calculated as mean +/− SEM of 3 independent experiments and reported
as percentage of control (TNF-α activated EC). Statistical analysis was carried out using one-way ANOVA employing Dunnett correction for
multiple comparisons. A statistical value of *P < 0.05 or greater was considered significant; $$$$ (p < 0.0001) vehicle vs control; ****P < 0.0001,
***P < 0.001, **P < 0.01 and *P < 0.05 treatments vs control (TNF-α activated EC).
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a PPAR-γ dependent mechanism.
Discussion
Food-derived biological active peptides found in many
different foods, including bovine milk, exert a physio-
logical effect in humans. The bioactive peptides are in-
active in their parent protein, but can be formed by
enzymatic or bacterial hydrolysis during gastrointestinal
digestion or during food processing (e.g., milk fermen-
tation). These are usually short residues (2–20 amino
acids), but may have more than 20 amino acids in size.
Milk proteins, including casein, are currently the main
source of several biofunctional peptides. The casein
composition of bovine milk can vary due to several fac-
tors, such as, breed [35], stage of lactation [36], season
[37], health [38] and genetic polymorphism [39]. At
present, it is unknown if the bioactivity reported in our
study may be affected by such changes, but the hydrolys-
ate used in the current study was generated from so-
dium caseinate powder, and not from milk, and, on
account of this, the possible variations in casein compos-
ition of bovine milk may hardly affect our hydrolysate
composition.
Numerous products containing bioactive peptides are
already on the market and casein derived peptides havealready found interesting applications as dietary supple-
ments and as pharmaceutical preparations [40]. Biofunc-
tional peptides exhibit activities that may be beneficial in
cardiovascular diseases [41,42] such as control of blood
pressure, cholesterol lowering, suppression of free rad-
ical formation and effects on platelet [43].
Endothelial dysfunction is a critical element in the
pathogenesis of atherosclerosis [18,19]. Endothelial cell ac-
tivation induces the expression of inflammatory cytokines
and adhesion molecules which stimulates leukocyte hom-
ing, adhesion and migration into the subendothelial space;
these processes are fundamental to atherosclerotic lesion
initiation and progression [3]. In the present study we re-
ported a novel anti-inflammatory bioactivity of the casein
hydrolysate derived by Enterococcus fermentation. We
found that bioactive peptides derived from Enterococcus
bacterial fermentation of sodium caseinate significantly
inhibited TNF-α-induced expression of adhesion mole-
cules as well as pro-inflammatory chemokine production
in EC. To assess the mechanism of these effects of casein
hydrolysate, we investigated the expression of mRNA for
the genes of E-selectin, vascular cell adhesion molecule 1
and intercellular adhesion molecule 1, their surface ex-
pression after stimulation with TNF-α and the production
of pro-atherogenic chemokines (MCP-1 and IL-8). The
gene and protein expression of these pro-inflammatory
Figure 5 Sodium casein-derived peptides modulate the expression of pro-inflammatory phenotype of EC via PPAR-γ dependent mechanisms.
TNF-α (0.5 ng/ml, 6 h) induced VCAM-1, ICAM-1 and E-sel expression was blocked by the PPAR-γ ligand, troglitazone (25 μM), similarly to the casein
hydrolysate (300 300 μg/ml). In the presence of GW9662 (10 μM), a PPAR-γ antagonist, the effects of both troglitazone and the casein hydrolysate were
completely reversed. (A) Gene expression levels of VCAM-1, ICAM-1 and E-sel were measured in EC treated with casein hydrolysate or troglitazone for
18 h and with or without GW9662 (10 μM), followed by 6 h stimulation with TNF-α (0.5 ng/ml). (B) Quantification of protein surface expression of
adhesion molecules was carried out by flow cytometric analysis. Data are expressed as mean ± SEM of 3 independent experiments. Data were reported
as percentage of control (TNF-α activated EC). Statistical comparison of one condition versus control was made by using Student’s unpaired t-test
assuming unequal variance; $$$ (p < 0.001) vehicle vs. control; **P < 0.01 and *P < 0.05 treatment vs. control; ##P < 0.01 and #P < 0.05 treatment vs. GW9662.
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activated EC were significantly inhibited by the treatment
of EC with casein hydrolysate, and these effects were ac-
companied by inhibition of the adhesion of the human
monocyte cell-line THP-1. VCAM-1, and ICAM-1 and E-
sel are well-known inflammatory mediators involved in
pathogenesis of atherosclerosis [44]. The levels of these
molecules also increase in association with cardiovascular
risk factors, and they have been correlated with measures
of atherosclerotic plaque disease and with adverse cardio-
vascular prognosis [45,46]. Cell adhesion molecules may
derive from multiple cellular types, but E-selectin is the
most specific marker for endothelial cell activation [47],
thus, our results suggest that the casein hydrolysate mayinhibit cell adhesion molecules expression by inhibiting
the activation of endhothelial cells.
Similar effects to the adhesion molecules inhibition by
casein hydrolysate were found with troglitazone, a well-
characterised PPAR-γ agonist. PPAR-γ is a negative
regulator of inflammatory processes such as adhesion
molecule expression and inflammatory chemokine pro-
duction in EC [28-30]. Given that casein hydrolysate
suppressed adhesion molecules and chemokine produc-
tion, we further examined whether this was due to
PPAR-γ activation. We investigated whether the effects
of casein hydrolysate on EC were suppressed by the spe-
cific PPAR-γ antagonist, GW9662, and found that the
inhibitory effects of casein hydrolysate on adhesion
Figure 6 Casein hydrolysate exerts its anti-inflammatory effects by suppressing NF-κB pathway activation through PPAR-γ dependent
mechanisms. Phosphorylation of the p65 subunit of NF-κB was used as an index of NF-kB activation. (A) EC were treated with casein hydrolysate
or troglitazone (25 μM) for 18 h and with or without GW9662 (10 μM), followed by 10 min stimulation with TNF-α (0.5 ng/ml). Phosphorylation of
p65 was estimated by Western blotting experiments (20 μg of total proteins) and β-actin was used as loading control. (B) Protein levels (assessed
as ratio of protein OD normalized to the OD of β-actin) were shown as percentage of control (TNF-α activated cell) (n = 3). Statistical comparison
of one condition versus control was made by using Student’s unpaired t-test assuming unequal variance; $$$ (p < 0.001) vehicle vs control;
**P < 0.01 and *P < 0.05 treatment vs control; ##P < 0.01 treatment vs GW9662.
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the EC were treated with GW9662. Similarly, GW9662
prevented the anti-inflammatory effects troglitazone in
TNF-α treated EC. The inhibitory effect of PPAR-γ on
EC inflammatory phenotype is mediated in part through
NF-κB [48], a key transcription factor in EC activation
and function [34]. In resting condition, NF-κB is main-
tained inactive in the cytosol of cells forming a complex
with its inhibitor subunit [49]. Upon stimulation by cy-
tokines, active NF-κB is free to enter the nucleus and to
regulate the transcription of several pro-inflammatory
genes, such as VCAM-1, ICAM-1, E-selectin, MCP-1
and IL-8 in EC. The phosphorylation of the p65 subunit
of NF-κB on serine-536 is an important step in the acti-
vation of the NF-κB pathway via activation of several ki-
nases including IκB kinases (IKKs) [50]. Therefore, the
effects of casein hydrolysate and troglitazone on the
phosphorylation of p65 subunit were examined as an
index of NF-kB pathway activation. Our results showed
that the PPAR-γ ligand troglitazone suppressed the acti-
vation of NF-κB by TNF-α in EC, decreasing the phos-
phorylation of p65 (Figure 6). The casein hydrolysate
induced similar responses in a dose dependent manner.
Moreover, GW9662 suppressed the effects of both tro-
glitazone and the hydrolysate, suggesting a role for
PPAR-γ in the NF-κB pathway modulation by the casein
hydrosylate. Given that NF-κB plays a role in regulating
the expression of adhesion molecules in EC, our data on
the suppression of NF-κB suggests that casein hydrolysatemay exert its inhibitory effects on adhesion molecules and
chemokine expression through NF-κB. Further evidence
that the effects of the casein hydrosylate are mediated by
PPAR-γ is provided by experiments demonstrating that its
effects on VCAM-1, ICAM-1 and E-sel expression are
suppressed in the presence of the PPAR-γ antagonist
GW9662.
It has been reported that other PPAR-γ activators,
such as cyclopentenone prostaglandins, might also exert
anti-inflammatory effects through suppression of NF-κB
activation in a PPAR-γ-independent manner via direct
inhibition of other steps of NF-κB pathway, such as IκB
kinase [51]. It has been also reported that PPAR-γ li-
gands may have anti-inflammatory effects in a PPAR-γ
and NF-κB independent manner interfering with other
pathways such as activation of ERK [52] or inhibition of
AP-1 pathways [53]. As the hydrolysate used in this
study is a complex mixture of peptides of different chain
length (Figure 1A), we cannot exclude the possibility
that, together with the direct effect on NF-κB through
PPAR-γ we showed here, the hydrosylate might exert its
anti-inflammatory effect by acting at other levels of NF-
κB activation or even by modulating other pathways. As
shown in Additional file 3: Figure S3, gene expression
analysis of adhesion molecules in EC treated with frac-
tions of the sodium caseinate-derived hydrolysate
showed that the fractions 0.5-5 KDa are the most bio-
active, suggesting that the anti-inflammatory activity of
the hydrolysate may be confined to the bio-active
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required to specifically identify the functional components
of the hydrolysate. Many of the known bioactive peptides
are multifunctional and can exhibit different bioactivities,
such as immunomodulation or antimicrobial, antioxidant,
antithrombotic, cholesterol lowering, and antihypertensive
properties [54-57]. Hypertension and thrombosis may be
controllable risk factors in the development of cardiovas-
cular diseases. Platelet activation and aggregation are cen-
tral events in thrombus formation, and dysregulation of
platelet physiology can contribute, together with endothe-
lial dysfunction, to the pathogenesis of thrombotic events
associated with hypertension [58,59]. Bioactive casein pep-
tides have been reported to have functional effects on the
cardiovascular system due to anti-thrombotic [60], anti-
hypertensive [61] and anti-obesity [62] effects, suggesting
a potential role in the control of cardiovascular diseases
[43]. Yamamoto [9] and Maeno [63] described an anti-
hypertensive effect of casein hydrolysates by using extra-
cellular Lactobacillus proteases, and, in an another study,
a sour milk product fermented with L. Helveticus and
Saccharomyces cerevisiae reduced arterial blood pressure
in rats [64] and humans [65]. Endothelial dysfunction is a
central element in the pathogenesis of atherosclerosis, and
some studies in animal and human models suggested that
bioactive peptides derived from β-casein (Val-Pro-Pro and
Ile-Pro-Pro), already known for their anti-hypertensive
properties, can reduce arterial stiffness and improve endo-
thelial functions [17,66,67]. Interestingly, a recent study
showed potential anti-inflammatory property of tryptic
hydrolysates of β-casein, mediated by the modulation of
NF-κB [13]; together with our study, it describes an anti-
inflammatory mechanism of action of casein hydrolysates.
In addition, in the present study, we reported an anti-
atherogenic bioactivity of the casein hydrolysate, and we
demonstrated that the hydrolysate acts by inhibiting tran-
scription factors (NF-κB and PPAR-γ) that are involved in
the regulation of several inflammatory pathways which, in
turn, are common to many diseases. Therefore, our results
may offer a useful basis to understand the molecular
mechanisms which may regulate many bioactivities attrib-
uted to milk derived bioactive peptides.
Conclusions
Our findings demonstrate that the hydrolysate obtained
by bacterial fermentation of sodium-caseinate suppresses
the NF-κB pathway and in turn inhibits the expression of
an EC inflammatory phenotype induced by TNF-α, by
down-regulating inflammatory-cell adhesion molecule and
chemokines expression. These effects were accompanied
by inhibition of the adhesion of a human monocyte cell-
line to TNF-α-activated human EC. This inhibitory effect
on TNF-α-induced inflammation was completely reversed
in the presence of the specific PPAR-γ inhibitor, GW9662,suggesting that the casein hydrolysate component(s) may
be a ligand for PPAR-γ and through this mechanism in-
hibit NF-κB activation. Further study is required to ex-
plore the potential for milk protein hydrolysate in human
atherosclerosis.Additional files
Additional file 1: Figure S1. Regenerated Sample of the Hydrolysate
was obtained by incubating a different batch of sodium caseinate with a
different batch of Enterococcus strain DPC763; the fermentation process
was carried out as described in the Methods section. The incubation of EC
with the regenerated sample showed similar results to the data obtained
with the hydrolysate previously studied here, confirming the reproducibility
of the procedure and of the study. (A) Gene expression analysis of adhesion
molecules VCAM-1, ICAM-1 and E-Sel in EC treated with regenerated sample
of the hydrolysate. EC were treated with samples for 18 h, followed by 6 h
stimulation with TNF-α (0.5 ng/ml). (B) Adhesion of human monocytes to EC
treated with the regenerated sample. EC were treated with samples for
18 h, followed by 6 h stimulation with TNF-α (0.5 ng/ml) and a static
adhesion assay with fluorescence-labelled THP-1 human monocytes was
performed. Adherent monocytes were measured in a plate fluorescence
reader with 485 nm excitation and 530 nm emission wavelength. (C) The
media from EC treated with the regenerated sample and activated with
TNF-α was assayed to measure MCP-1 and IL-8 concentration by ELISA. Data
were calculated as mean +/− SEM of 3 independent experiments. Data were
reported as percentage of control (TNF-α activated EC); Statistical analysis
was carried out using one-way ANOVA employing Dunnett correction for
multiple comparisons. A statistical value of *P < 0.05 or greater was considered
significant; $$$$ (p < 0.0001) vehicle vs control; ****P < 0.0001, ***P < 0.001
and **P < 0.01 treatments vs control (TNF-α activated EC).
Additional file 2: Figure S2. Gene expression analysis of adhesion
molecules in EC treated with the “Control Samples”. EC were treated with
control sample (no Enterococcus in the fermentation process) (A), with
Enterococcus strain PS063 (B) and with Enterococcus strain FHI0100 (C) for
18 h, followed by 6 h stimulation with TNF-α (0.5 ng/ml). RNA extraction
and real-time PCR were performed as described in the Methods section.
We used these two different Enterococcus strains as control samples
because they could be compared to the strain used to produce the
hydrolysate studied here (Enterococcus strain DPC763) since these have
similar proteolytic profiles and base additions in the preparation process.
As shown, these samples do not have any significant effect on adhesion
molecules expression in EC, demonstrating that the effects of the hydrolysate
studied here is due to the specific bioactive peptides generated by the
bacterial fermentation with Enterococcus strain DPC763 and these effects are
not due to a general hydrolysed material or pH effect.
Additional file 3: Figure S3. Gene expression analysis of adhesion
molecules in EC treated with fractions of sodium caseinate-derived
hydrolysate. For fractions preparation the hydrolysate was resuspended in
water and spun at 5000 rpm for 5 min, filtered through a 0.45um filter
and then fractionated through a series of Millipore membranes of varying
pore size (Merck Millipore, Billerica, MA) to generate specific protein
fractions with enriched size ranges. EC were treated with fractions
(150ug/ml) for 18 h, followed by 6 h stimulation with TNF-α (0.5 ng/ml).
RNA extraction and real-time PCR were performed as described in the
Methods section. Data were reported as percentage of control (TNF-α
activated EC).Statistical analysis was carried out using one-way ANOVA
employing Dunnett correction for multiple comparisons. A statistical
value of *P < 0.05 or greater was considered significant; $$$$ (p < 0.0001)
vehicle vs control; ***P < 0.001, **P < 0.01 and *P < 0.05 treatments vs
control (TNF-α activated EC).Competing interests
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